Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience

M. Zemanova, R. Pirker, L. Petruzelka, Z. Zbozínkova, D. Jovanovic, M. Rajer, K. Bogos, G. Purkalne, V. Ceriman, S. Chaudhary, I. Richter, J. Kufa, L. Jakubikova, M. Zemaitis, M. Cernovska, L. Koubkova, Z. Vilasova, K. Dieckmann, A. Farkas, J....

. 2020 ; 54 (2) : 209-220. [pub] 20200528

Language English Country Poland

Document type Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026703

Background Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. Patients and methods This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026703
003      
CZ-PrNML
005      
20211026132704.0
007      
ta
008      
211013s2020 pl f 000 0|eng||
009      
AR
024    7_
$a 10.2478/raon-2020-0026 $2 doi
035    __
$a (PubMed)32463394
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Zemanova, Milada $u 1st Faculty of Medicine of Charles University in Prague, Prague Czech Republic
245    10
$a Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience / $c M. Zemanova, R. Pirker, L. Petruzelka, Z. Zbozínkova, D. Jovanovic, M. Rajer, K. Bogos, G. Purkalne, V. Ceriman, S. Chaudhary, I. Richter, J. Kufa, L. Jakubikova, M. Zemaitis, M. Cernovska, L. Koubkova, Z. Vilasova, K. Dieckmann, A. Farkas, J. Spasic, K. Fröhlich, A. Tiefenbacher, V. Hollosi, J. Kultan, I. Kolarová, J. Votruba
520    9_
$a Background Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. Patients and methods This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.
650    _2
$a adenokarcinom $x patologie $x terapie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a mozek $x diagnostické zobrazování $7 D001921
650    _2
$a bronchoskopie $x statistika a číselné údaje $7 D001999
650    _2
$a nemalobuněčný karcinom plic $x diagnóza $x patologie $x terapie $7 D002289
650    _2
$a spinocelulární karcinom $x patologie $x terapie $7 D002294
650    _2
$a kombinovaná terapie $x metody $x statistika a číselné údaje $7 D003131
650    _2
$a endosonografie $x statistika a číselné údaje $7 D019160
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a geny erbB-1 $7 D018773
650    _2
$a lidé $7 D006801
650    _2
$a ultrazvukem navigovaná biopsie $x statistika a číselné údaje $7 D061705
650    _2
$a nádory plic $x diagnóza $x patologie $x terapie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a nekuřáci $x statistika a číselné údaje $7 D000078405
650    _2
$a PET/CT $7 D000072078
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a prospektivní studie $7 D011446
650    _2
$a stupeň závažnosti nemoci $7 D012720
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pirker, Robert $u Department of Medicine I, Medical University of Vienna, Vienna, Austria
700    1_
$a Petruzelka, Lubos $u 1st Faculty of Medicine of Charles University in Prague, Prague Czech Republic
700    1_
$a Zbozínkova, Zuzana $u Institute of Biostatistic and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Jovanovic, Dragana $u Clinic for Pulmonology, Clinical Centre of Serbia, Belgrade, Serbia
700    1_
$a Rajer, Mirjana $u Institute of Oncology, Ljubljana, Slovenia
700    1_
$a Bogos, Krisztina $u National Koranyi Institute of TB and Pulmonology, Budapest, Hungary
700    1_
$a Purkalne, Gunta $u Pauls Stradins Clinical University Hospital, Riga, Latvia
700    1_
$a Ceriman, Vesna $u Clinic for Pulmonology, Clinical Centre of Serbia, Belgrade, Serbia
700    1_
$a Chaudhary, Subhash $u Comprehensive Oncology Center, Nový Jičín, Liberec Czech Republic
700    1_
$a Richter, Igor $u Comprehensive Oncology Center, Liberec, Czech Republic
700    1_
$a Kufa, Jirí $u Clinic for Pneumology & Tuberculosis, Faculty of Medicine, Palacký University, Olomouc, Czech Republic
700    1_
$a Jakubikova, Lenka $u Clinic for Pneumology & Tuberculosis, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zemaitis, Marius $u Hospital of LUHS Kauno Klinikos, Kauno, Lithuania
700    1_
$a Cernovska, Marketa $u Thomayer Hospital, Prague, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pulmonology, University Hospital Motol, Prague, Czech Republic
700    1_
$a Vilasova, Zdenka $u Comprehensive Oncology Center and Multiscan, Pardubice, Czech Republic
700    1_
$a Dieckmann, Karin $u Department of Radiotherapy, Medical University of Vienna, Vienna, Austria
700    1_
$a Farkas, Attila $u Department of Thoracic Surgery, Semmelweis University, Budapest, Hungary
700    1_
$a Spasic, Jelena $u Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
700    1_
$a Fröhlich, Katerina $u Institute of Biostatistic and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Tiefenbacher, Andreas $u Department of Medicine I, Medical University of Vienna, Vienna, Austria
700    1_
$a Hollosi, Virag $u National Koranyi Institute of TB and Pulmonology, Budapest, Hungary
700    1_
$a Kultan, Juraj $u Clinic for Pneumology & Tuberculosis, Faculty of Medicine, Palacký University, Olomouc, Czech Republic
700    1_
$a Kolarová, Iveta $u Comprehensive Oncology Center and Multiscan, Pardubice, Czech Republic
700    1_
$a Votruba, Jiri $u 1st Faculty of Medicine of Charles University in Prague, Prague Czech Republic
773    0_
$w MED00004048 $t Radiology and oncology $x 1581-3207 $g Roč. 54, č. 2 (2020), s. 209-220
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32463394 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132710 $b ABA008
999    __
$a ok $b bmc $g 1715442 $s 1147210
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 54 $c 2 $d 209-220 $e 20200528 $i 1581-3207 $m Radiology and oncology $n Radiol. oncol. (Tik. izd.) $x MED00004048
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options